IL2RB and neoplasm: The results demonstrated unexpected, substantial synergy of the “Triplet”Ad-p53 + CD122/132 + anti-PD-1 therapies that resulted in potentially curative treatment associated with the complete tumor remissions of both the primary and contralateral tumors with significantly superior abscopal effects on distant tumors not injected with Ad-p53 tumor suppressor therapy.